论文部分内容阅读
目的:探讨前列地尔治疗高龄糖尿病伴慢性肾脏病患者的疗效和安全性。方法:选择2015年1月至2016年10月期间本院收治的62高龄糖尿病伴慢性肾脏病患者作为研究对象,随机分为对照组和观察组,各31例。在饮食治疗、降糖、降压等常规治疗基础上:观察组采用前列地尔治疗,对照组患者采用银杏达莫注射液治疗,监测两组用药安全性,并比较两组患者疗效。结果:观察组总有效率(90.32%)显著高于对照组(77.42%),组间差异p<0.05,具有统计学意义。观察组不良反应发生率(12.90%)显著低于对照组(29.03%),组间差异p<0.05,具有统计学意义。结论:前列地尔治疗高龄糖尿病伴慢性肾脏病疗效可靠,不良反应较少,临床疗效安全可靠。
Objective: To investigate the efficacy and safety of alprostadil in the treatment of elderly diabetic patients with chronic kidney disease. Methods: Sixty-two elderly patients with chronic kidney disease admitted from January 2015 to October 2016 in our hospital were randomly divided into control group and observation group, with 31 cases in each group. On the basis of diet, hypoglycemic, antihypertensive and other conventional treatment, the observation group was treated with alprostadil, and the control group was treated with Yinxingdamo injection. The safety of the two groups was monitored, and the curative effect of the two groups was compared. Results: The total effective rate (90.32%) in the observation group was significantly higher than that in the control group (77.42%), the difference between groups was p <0.05, with statistical significance. The incidence of adverse reactions in the observation group (12.90%) was significantly lower than that in the control group (29.03%), the difference between groups was p <0.05, with statistical significance. Conclusion: Alprostadil is effective in treating elderly patients with diabetic nephropathy and chronic kidney disease with less adverse reactions, and the clinical efficacy is safe and reliable.